dc.creator | Rodríguez-Arbolí, Eduardo | es |
dc.creator | Martínez-Cuadrón, David | es |
dc.creator | Rodríguez-Veiga, Rebeca | es |
dc.creator | Carrillo-Cruz, Estrella | es |
dc.creator | Gil-Cortés, Cristina | es |
dc.creator | Serrano-López, Josefina | es |
dc.creator | Pérez Simón, José Antonio | es |
dc.creator | Montesinos, Pau | es |
dc.date.accessioned | 2022-09-30T10:44:14Z | |
dc.date.available | 2022-09-30T10:44:14Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Rodríguez-Arbolí, E., Martínez-Cuadrón, D., Rodríguez-Veiga, R., Carrillo-Cruz, E., Gil-Cortés, C., Serrano-López, J.,...,Montesinos, P. (2021). Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.. Transplantation and Cellular Therapy, 27 (4), 311.e1-311.e10. | |
dc.identifier.issn | 2666-6367 | es |
dc.identifier.uri | https://hdl.handle.net/11441/137525 | |
dc.description.abstract | Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological enti-
ties with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal
postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study,
we compared outcomes in IRcyto AML recipients of autologous (autoSCT) (n = 312) or allogeneic stem cell trans-
plantation (alloSCT) (n = 279) in first complete remission (CR1). Molecular risk was defined based on CEBPA,
NPM1, and FLT3-ITD mutational status, per European LeukemiaNet 2017 criteria. Five-year overall survival (OS) in
patients with favorable molecular risk (FRmol) was 62% (95% confidence interval [CI], 50-72) after autoSCT and
66% (95% CI, 41-83) after matched sibling donor (MSD) alloSCT (P = .68). For patients of intermediate molecular
risk (IRmol), MSD alloSCT was associated with lower cumulative incidence of relapse (P < .001), as well as with
increased nonrelapse mortality (P = .01), as compared to autoSCT. The 5-year OS was 47% (95% CI, 34-58) after
autoSCT and 70% (95% CI, 59-79) after MSD alloSCT (P = .02) in this patient subgroup. In a propensity-score
matched IRmol subcohort (n = 106), MSD alloSCT was associated with superior leukemia-free survival (hazard
ratio [HR] 0.33, P = .004) and increased OS in patients alive 1 year after transplantation (HR 0.20, P = .004). These
results indicate that, within IRcyto AML in CR1, autoSCT may be a valid option for FRmol patients, whereas MSD
alloSCT should be the preferred postremission strategy in IRmol patients | es |
dc.format | application/pdf | es |
dc.format.extent | 10 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | Transplantation and Cellular Therapy, 27 (4), 311.e1-311.e10. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Acute myeloid leukemia | es |
dc.subject | Allogeneic stem cell transplant | es |
dc.subject | Autologous stem cell transplant | es |
dc.title | Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study. | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | http://europepmc.org/abstract/med/33836871 | es |
dc.identifier.doi | 10.1016/j.jtct.2020.12.029 | es |
dc.journaltitle | Transplantation and Cellular Therapy | es |
dc.publication.volumen | 27 | es |
dc.publication.issue | 4 | es |
dc.publication.initialPage | 311.e1 | es |
dc.publication.endPage | 311.e10 | es |